HKSE:03378 (China)
Â
Class H
HK$
27.56
+1.56 (+6%)
Jul 30
Business Description
Hanx Biopharmaceuticals (Wuhan) Co Ltd
ISIN : CNE100007C34
Share Class Description:
HKSE:03378: Class HTotal Employee Number:
55Compare
Compare
Traded in other countries / regions
03378.Hong Kong IPO Date
2025-12-23Description
Hanx Biopharmaceuticals (Wuhan) Co Ltd is a biotech company with in-house capabilities in structural biology, translational medicine, and clinical development, focused on developing immunotherapeutic products. Its product pipeline comprises one Core Product and nine other pipeline candidates: three clinical-stage drug candidates focused on oncology, including its Core Product HX009 and Key Products HX301 and HX044; and seven preclinical-stage drug candidates, including an antibody drug conjugate, a bispecific antibody, and a monoclonal antibody for both autoimmune and oncology markets.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 11.67 | |||||
Equity-to-Asset | 0.75 | |||||
Debt-to-Equity | 0.08 | |||||
Debt-to-EBITDA | -0.44 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 15.19 | |||||
9-Day RSI | 23.65 | |||||
14-Day RSI | 32.32 | |||||
3-1 Month Momentum % | -12.82 | |||||
6-1 Month Momentum % | 64 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.27 | |||||
Quick Ratio | 7.27 | |||||
Cash Ratio | 6.86 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | -16.78 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -30.52 | |||||
ROA % | -18.45 | |||||
ROIC % | -39.8 | |||||
ROC (Joel Greenblatt) % | -616.74 | |||||
ROCE % | -23.53 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 4.87 | |||||
Price-to-Tangible-Book | 4.87 | |||||
EV-to-EBIT | -25.29 | |||||
EV-to-EBITDA | -26.56 | |||||
EV-to-FCF | -32.34 | |||||
| Price-to-Net-Current-Asset-Value | 7.49 | |||||
| Price-to-Net-Cash | 8.2 | |||||
Earnings Yield (Greenblatt) % | -3.95 | |||||
FCF Yield % | -3.12 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Hanx Biopharmaceuticals (Wuhan) Co Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | |||
| EPS (TTM) (HK$) | -1.226 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 32.32 | ||
| 14-Day ATR (HK$) | 1.834712 | ||
| 20-Day SMA (HK$) | 28.038 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (HK$) | 13.48 - 32.94 | ||
| Shares Outstanding (Mil) | 134.06 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Hanx Biopharmaceuticals (Wuhan) Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Hanx Biopharmaceuticals (Wuhan) Co Ltd Stock Events
| Event | Date | Price (HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Hanx Biopharmaceuticals (Wuhan) Co Ltd Frequently Asked Questions
What is Hanx Biopharmaceuticals (Wuhan) Co Ltd(HKSE:03378)'s stock price today?
The current price of HKSE:03378 is HK$27.56. The 52 week high of HKSE:03378 is HK$32.94 and 52 week low is HK$13.48.
When is next earnings date of Hanx Biopharmaceuticals (Wuhan) Co Ltd(HKSE:03378)?
The next earnings date of Hanx Biopharmaceuticals (Wuhan) Co Ltd(HKSE:03378) is .
Does Hanx Biopharmaceuticals (Wuhan) Co Ltd(HKSE:03378) pay dividends? If so, how much?
Hanx Biopharmaceuticals (Wuhan) Co Ltd(HKSE:03378) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Hanx Biopharmaceuticals (Wuhan) Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers